![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
20
Kyongbo Pharmaceutical Co., Ltd. Asan-si Kr, based in South Korea, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
One of their significant offerings is Ceftazidime Pentahydrate, Sterile, supported by a 'Withdrawn by Holder' Certificate of Suitability (CEP) with the number R1-CEP 2011-390 - Rev 00
This Chemical Type CEP, issued on November 21, 2018, remains in force until July 27, 2021, ensuring its reliability within the pharmaceutical industry.
Substance Number 1405 associated with this CEP further emphasizes